OBJECTIVE: This study was to assess the effect of intravenous thrombolysis combined with mechanical thrombectomy on neurological function and the short-term prognosis of patients with acute cerebral infarction (ACI). METHODS: A total of 120 patients with ACI admitted to our hospital from January 2019 to January 2020 were selected as research objects, and randomized into Group A (n=60) or Group B (n=60). Patients in both groups were treated with intravenous thrombolysis. Group B received ACI conventional treatment and intravenous thrombolysis, while Group A was additionally given mechanical thrombectomy. Then the neurological function scores, serum factor levels, vascular recanalization rate, incidence of adverse reactions, Thrombolysis in Myocardial Infarction (TIMI) grade flow, and effective rate of treatment were compared between the two groups. The clinical trial is available at https://clinicaltrials.gov/, ClinicalTrials.gov Identifier: NCT03502411. RESULTS: The neurological function scores of Group A were apparently lower than those of Group B one month after treatment (P<0.001). After treatment, Group A yielded a superior serum factor level compared to Group B (P<0.001), and also showed a higher recanalization rate of blood vessels and a notably lower adverse reaction rate (all P<0.05). CONCLUSION: Intravenous thrombolysis combined with mechanical thrombectomy can accelerate the recovery of neurological function in patients with ACI, and yield a more promising outcome in terms of the patient's vascular recanalization rate compared with the monotherapy. It can also reduce the adverse reaction rate of patients to ensure a better short-term prognosis. AJTR
OBJECTIVE: This study was to assess the effect of intravenous thrombolysis combined with mechanical thrombectomy on neurological function and the short-term prognosis of patients with acute cerebral infarction (ACI). METHODS: A total of 120 patients with ACI admitted to our hospital from January 2019 to January 2020 were selected as research objects, and randomized into Group A (n=60) or Group B (n=60). Patients in both groups were treated with intravenous thrombolysis. Group B received ACI conventional treatment and intravenous thrombolysis, while Group A was additionally given mechanical thrombectomy. Then the neurological function scores, serum factor levels, vascular recanalization rate, incidence of adverse reactions, Thrombolysis in Myocardial Infarction (TIMI) grade flow, and effective rate of treatment were compared between the two groups. The clinical trial is available at https://clinicaltrials.gov/, ClinicalTrials.gov Identifier: NCT03502411. RESULTS: The neurological function scores of Group A were apparently lower than those of Group B one month after treatment (P<0.001). After treatment, Group A yielded a superior serum factor level compared to Group B (P<0.001), and also showed a higher recanalization rate of blood vessels and a notably lower adverse reaction rate (all P<0.05). CONCLUSION: Intravenous thrombolysis combined with mechanical thrombectomy can accelerate the recovery of neurological function in patients with ACI, and yield a more promising outcome in terms of the patient's vascular recanalization rate compared with the monotherapy. It can also reduce the adverse reaction rate of patients to ensure a better short-term prognosis. AJTR
Authors: Simon F De Meyer; Tommy Andersson; Blaise Baxter; Martin Bendszus; Patrick Brouwer; Waleed Brinjikji; Bruce Cv Campbell; Vincent Costalat; Antoni Dávalos; Andrew Demchuk; Diederik Dippel; Jens Fiehler; Urs Fischer; Michael Gilvarry; Matthew J Gounis; Jan Gralla; Olav Jansen; Tudor Jovin; David Kallmes; Pooja Khatri; Kennedy R Lees; Elena López-Cancio; Charles Majoie; Henk Marquering; Ana Paula Narata; Raul Nogueira; Peter Ringleb; Adnan Siddiqui; István Szikora; David Vale; Rüdiger von Kummer; Albert J Yoo; Werner Hacke; David S Liebeskind Journal: Int J Stroke Date: 2017-05-23 Impact factor: 5.266
Authors: Rody El Nawar; Jennifer Yeung; Julien Labreuche; Marie-Laure Chadenat; Duc Long Duong; Maxime De Malherbe; Yves-Sebastien Cordoliani; Bertrand Lapergue; Fernando Pico Journal: Front Neurol Date: 2019-08-27 Impact factor: 4.003